TSE:JWEL
37.96
0.75
(2.02%)
Founded in 1922, Jamieson is Canada's leading branded manufacturer, distributor and marketer of high quality natural health products.
More at Wikipedia
Analysis and Opinions about JWEL-T
Signal
Opinion
Expert
Chart
BUY WEAKNESS
BUY WEAKNESS
April 28, 2021
Interesting, good company, profitable. A bit rich now. He was worried about private labels taking market share. Could buy it on the right dip. He's looking at it.
Show full opinionHide full opinion
Interesting, good company, profitable. A bit rich now. He was worried about private labels taking market share. Could buy it on the right dip. He's looking at it.
BUY
BUY
March 3, 2021
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Revenues beat street estimates by 4%. EBITDA was 2% better at $29M. It is trading at 26x earnings, which is reasonably considering the high growth expectations. There are competitors but they have strong market share. A higher risk buy for growth and some income. Unlock Premium - Try 5i Free
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Revenues beat street estimates by 4%. EBITDA was 2% better at $29M. It is trading at 26x earnings, which is reasonably considering the high growth expectations. There are competitors but they have strong market share. A higher risk buy for growth and some income. Unlock Premium - Try 5i Free
BUY
BUY
December 14, 2020
She does not follow that small a capitalization stock closely. They are a well positioned player in the space. Their growth opportunities look positive.
Show full opinionHide full opinionShe does not follow that small a capitalization stock closely. They are a well positioned player in the space. Their growth opportunities look positive.
WATCH
WATCH
December 4, 2020
A great company and it has profited from the pandemic. People are becoming more health conscious. It is well-positioned to take advantage of the trend. Earnings still have a ways to grow to make the multiples attractive. Trailing 12-month earnings are .64 cents, which makes it at 36x earnings. He would like to see it more around 25x earnings, around the mid-to-high 20s.
Show full opinionHide full opinionA great company and it has profited from the pandemic. People are becoming more health conscious. It is well-positioned to take advantage of the trend. Earnings still have a ways to grow to make the multiples attractive. Trailing 12-month earnings are .64 cents, which makes it at 36x earnings. He would like to see it more around 25x earnings, around the mid-to-high 20s.
BUY WEAKNESS
BUY WEAKNESS
November 25, 2020
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Business has reamiend good and earnings growth continues to be expected. They raised dividends in August with more room to grow. The $6 decline is probably over done. Unlock Premium - Try 5i Free
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Business has reamiend good and earnings growth continues to be expected. They raised dividends in August with more room to grow. The $6 decline is probably over done. Unlock Premium - Try 5i Free
BUY
BUY
November 11, 2020
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Sales beat expectations by 6% and earnings also beat estimates by 2%. Guidance was raised, which is also positive. The pull back that brought it down 16% is more market related than to do with the stock itself. It is a good time to add to this position. Unlock Premium - Try 5i Free
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Sales beat expectations by 6% and earnings also beat estimates by 2%. Guidance was raised, which is also positive. The pull back that brought it down 16% is more market related than to do with the stock itself. It is a good time to add to this position. Unlock Premium - Try 5i Free
BUY
BUY
September 7, 2020
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Covid has helped the company with consumers more aware of health. They beat sale estimates last quarter but missed on EPS. It’s trading within its expected growth rate. The health trend should be sustained even after covid. Unlock Premium - Try 5i Free
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Covid has helped the company with consumers more aware of health. They beat sale estimates last quarter but missed on EPS. It’s trading within its expected growth rate. The health trend should be sustained even after covid. Unlock Premium - Try 5i Free
BUY WEAKNESS
BUY WEAKNESS
April 24, 2020
Just looking at your local drug store, all the shelves have been stripped bare for their products. People are taking more supplements and he thinks that will continue. The stock is at 29 times PE, but technically it is bullish. He thinks analysts will continue to increase earnings outlooks to justify the costs.
Show full opinionHide full opinionJust looking at your local drug store, all the shelves have been stripped bare for their products. People are taking more supplements and he thinks that will continue. The stock is at 29 times PE, but technically it is bullish. He thinks analysts will continue to increase earnings outlooks to justify the costs.
BUY
BUY
November 25, 2019
A fine IPO performer; they did a good job to ensure that private equity fund involved got cleaned out, so that overhang didn't happen. They just put out a strong report with good international growth. This may be added to an index. Not a cheap stock, but they boast earnings growth and a strong brand. He owns a lot of this.
Show full opinionHide full opinionA fine IPO performer; they did a good job to ensure that private equity fund involved got cleaned out, so that overhang didn't happen. They just put out a strong report with good international growth. This may be added to an index. Not a cheap stock, but they boast earnings growth and a strong brand. He owns a lot of this.
HOLD
HOLD
June 13, 2019
They did a good job of getting the private equity guys out of it so there was lots for individual investors. They are gearing up for a better second half.
Show full opinionHide full opinionThey did a good job of getting the private equity guys out of it so there was lots for individual investors. They are gearing up for a better second half.
HOLD
HOLD
January 17, 2019
Vitamins and health supplements, protein supplements. They missed on earnings. It is a great Canadian company. A pickup in the cold and flu season would benefit them. They are trying to penetrate the Chinese market. They Manufacture in Winsor and Scarborough.
Show full opinionHide full opinionVitamins and health supplements, protein supplements. They missed on earnings. It is a great Canadian company. A pickup in the cold and flu season would benefit them. They are trying to penetrate the Chinese market. They Manufacture in Winsor and Scarborough.
WATCH
WATCH
November 19, 2018
A stable, high-quality business. When it IPO'd, the market over-rewarded it, but the stock has since corrected to something attractive. The healthy trend works for them. he's studying it.
Show full opinionHide full opinionA stable, high-quality business. When it IPO'd, the market over-rewarded it, but the stock has since corrected to something attractive. The healthy trend works for them. he's studying it.
HOLD
HOLD
October 17, 2018
He likes the trend towards health and wellness through supplements and protein shakes. The company has been given a license to sell their branded product in China. His fund will continue to hold this stock.
He likes the trend towards health and wellness through supplements and protein shakes. The company has been given a license to sell their branded product in China. His fund will continue to hold this stock.
PAST TOP PICK
PAST TOP PICK
September 20, 2018
(A Top Pick July 20/17, Up 56%) He looks for companies that dominate their market. This is the number one consumer healthcare brand. More than the next 5 largest competitors combined. It was a show-me story at the time. It needs to penetrate other geographical markets like China for continued growth. It is fairly valued at this price.
(A Top Pick July 20/17, Up 56%) He looks for companies that dominate their market. This is the number one consumer healthcare brand. More than the next 5 largest competitors combined. It was a show-me story at the time. It needs to penetrate other geographical markets like China for continued growth. It is fairly valued at this price.
COMMENT
COMMENT
March 8, 2018
Smaller cap than she would buy. Vitamin manufacturer and retailer. A good one to own.
Smaller cap than she would buy. Vitamin manufacturer and retailer. A good one to own.
Jamieson Wellness(JWEL-T) Rating
Ranking : 5 out of 5
Bullish - Buy Signals / Votes : 6
Neutral - Hold Signals / Votes : 0
Bearish - Sell Signals / Votes : 0
Total Signals / Votes : 6
Jamieson Wellness(JWEL-T) Frequently Asked Questions
What is Jamieson Wellness stock symbol?
Jamieson Wellness is a Canadian stock, trading under the symbol JWEL-T on the Toronto Stock Exchange (JWEL-CT). It is usually referred to as TSX:JWEL or JWEL-T
Is Jamieson Wellness a buy or a sell?
In the last year, 6 stock analysts published opinions about JWEL-T. 6 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is BUY on WEAKNESS. Read the latest stock experts' ratings for Jamieson Wellness.
Is Jamieson Wellness a good investment or a top pick?
Jamieson Wellness was recommended as a Top Pick by Stephen Takacsy, B. Eng, MBA on 2021-04-28. Read the latest stock experts ratings for Jamieson Wellness.
Why is Jamieson Wellness stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Jamieson Wellness worth watching?
6 stock analysts on Stockchase covered Jamieson Wellness In the last year. It is a trending stock that is worth watching.
What is Jamieson Wellness stock price?
On 2021-05-14, Jamieson Wellness (JWEL-T) stock closed at a price of $37.96.
